Scd

GBT Announces New Employment Inducement Grants

Retrieved on: 
Monday, March 8, 2021
Health in Africa, Hematopathology, Sickle cell disease, Branches of biology, Stearoyl-CoA desaturase-1, Scd, Clinical medicine, Medical specialties

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Key Points: 
  • These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by GBTs board of directors in January 2017 and has been amended and restated from time to time.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.

GBT Opens 2021 ACCEL Grant Program, Providing up to $500,000 in Support to the Sickle Cell Disease Community

Retrieved on: 
Tuesday, March 2, 2021
Branches of biology, Health in Africa, Hematopathology, Sickle cell disease, Medicine, Scd, Stearoyl-CoA desaturase-1, COVID-19 vaccine, Accel, GBT, Clinical medicine

With the doubling of funds for 2021, this years priority areas for grant proposals have expanded to include initiatives that address racial equity and COVID-19 vaccine awareness amongst the SCD community.

Key Points: 
  • With the doubling of funds for 2021, this years priority areas for grant proposals have expanded to include initiatives that address racial equity and COVID-19 vaccine awareness amongst the SCD community.
  • GBT is accepting proposals for the ACCEL program through Friday, April 23, 2021, at 11:59 p.m. Pacific time.
  • A panel of GBT management and external stakeholders with expertise in the issues affecting people with SCD will review proposal submissions.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.

GBT Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Friday, February 19, 2021
Health in Africa, Hematopathology, Sickle cell disease, Branches of biology, Scd, Stearoyl-CoA desaturase-1, Clinical medicine, Medical specialties

ET; and

Key Points: 
  • ET; and
    Cowen 41st Annual Health Care Conference on March 1 at 11:40 a.m.
  • Ted W. Love, M.D., president and CEO of GBT, will also participate in a virtual panel, Non-Malignant Hematology, at this conference on March 1 at 2:40 p.m.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • In addition, GBTs drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

GBT Announces New Employment Inducement Grants

Retrieved on: 
Friday, February 5, 2021
Health in Africa, Hematopathology, Sickle cell disease, Branches of biology, Stearoyl-CoA desaturase-1, Scd, Clinical medicine, Medical specialties

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Key Points: 
  • These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by GBTs board of directors in January 2017 and has been amended and restated from time to time.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.

GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States

Retrieved on: 
Thursday, February 4, 2021
Sickle-cell disease, Clinical medicine, Branches of biology, Health sciences, Breakthrough therapy, Voxelotor, Sickle cell disease, Scd

SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is currently enrolling.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that an expanded access protocol (EAP) for Oxbryta (voxelotor) in pediatric patients with sickle cell disease (SCD) has been initiated and is currently enrolling.
  • Early intervention and treatment of sickle cell disease are critical and have shown potential to modify the course of this devastating disease.
  • Oxbryta is approved in the United States for the treatment of SCD in patients ages 12 years and older.
  • There are multiple clinical sites across the United States participating in the treatment protocol.

GBT Announces New Employment Inducement Grants

Retrieved on: 
Thursday, January 7, 2021
Health in Africa, Hematopathology, Sickle cell disease, Branches of biology, Stearoyl-CoA desaturase-1, Scd, Clinical medicine, Medical specialties

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Key Points: 
  • These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • The Plan was adopted by GBTs board of directors in January 2017 and has been amended and restated from time to time.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.

GBT Announces Participation at the 39th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 5, 2021
Branches of biology, Health in Africa, Hematopathology, Sickle cell disease, Scd, Stearoyl-CoA desaturase-1, GBT, Clinical medicine, Medical specialties

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 11:40 a.m. Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual presentation at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021, at 11:40 a.m. Eastern Time.
  • The presentation and Q&A session will be webcast live from GBTs website at www.gbt.com in the Investors section.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • In addition, GBTs drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

GBT Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 25, 2020
Branches of biology, Clinical medicine, Medical specialties, Health in Africa, Hematopathology, Sickle cell disease, Scd, Stearoyl-CoA desaturase-1, Hematologic disease, Sickle-cell disease

The fireside chats will be webcast live from GBTs website at www.gbt.com in the Investors section.

Key Points: 
  • The fireside chats will be webcast live from GBTs website at www.gbt.com in the Investors section.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • In addition, GBTs drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
  • To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news .

GBT Announces Participation at the Stifel 2020 Virtual Healthcare Conference

Retrieved on: 
Friday, November 13, 2020
Health in Africa, Hematopathology, Sickle cell disease, Scd, Branches of biology, Fireside chats, GBT, Stearoyl-CoA desaturase-1, Clinical medicine, Medical specialties

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc.(GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 2:00 p.m. Eastern Time.
  • The fireside chat will be webcast live from GBTs website at www.gbt.com in the Investors section.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • In addition, GBTs drug discovery teams are working on new targets to develop the next wave of treatments for SCD.

GBT Announces New Employment Inducement Grants

Retrieved on: 
Monday, November 9, 2020
Health in Africa, Hematopathology, Sickle cell disease, Branches of biology, Stearoyl-CoA desaturase-1, Scd, Satélite de Coleta de Dados, Clinical medicine, Medical specialties

These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).

Key Points: 
  • These awards were made under GBTs Amended and Restated 2017 Inducement Equity Plan (the Plan).
  • The above-described awards were each granted as an inducement material to the employees entering into employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), and were granted pursuant to the terms of the Plan.
  • Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder.
  • In addition, GBTs drug discovery teams are working on new targets to develop the next wave of treatments for SCD.